Benchmark Holdings Plc Logo

Benchmark Holdings Plc

Aquaculture biotech providing nutrition and health solutions for sustainable farming.

BMK | IL

Overview

Corporate Details

ISIN(s):
GB00BGHPT808 (+1 more)
LEI:
2138001UQHM4VZGXUJ19
Country:
United Kingdom
Address:
4 PARK SQUARE, THORNCLIFFE PARK, CHAPELTOWN, S35 2PH SHEFFIELD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Benchmark Holdings plc is a leading aquaculture biotechnology company dedicated to driving sustainability in the industry. The company's mission is to provide aquaculture producers with mission-critical products and solutions that enhance farming efficiency, animal health, and welfare. Benchmark's operations are centered around two key divisions: Advanced Nutrition and Health. Its portfolio includes specialized diets, probiotics, vaccines, medicines, and other health products designed to improve productivity and sustainability for its global customer base. By combining biology and technology, Benchmark supports the growth of a sustainable food supply chain.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-18 08:00
Delisting Announcement
Cancellation of Admissions to Trading
English 11.1 KB
2025-08-15 08:00
Delisting Announcement
Last day of trading
English 6.0 KB
2025-08-15 08:00
Delisting Announcement
Benchmark Holdings plc – Last day of trading
English 1.1 KB
2025-08-08 14:06
Delisting Announcement
Update on the cancellation of trading of shares
English 16.2 KB
2025-08-08 14:00
Delisting Announcement
Update on Euronext Oslo Børs approval of the cancellation of the trading of Ben…
English 4.1 KB
2025-08-08 13:55
Delisting Announcement
Benchmark Holdings plc – Decision on date of delisting
English 749 bytes
2025-08-08 13:55
Delisting Announcement
Benchmark Holdings plc – Vedtak om dato for strykning
Norwegian 766 bytes
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 16.7 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights - Attachment: BMK RNS TVR 31 July.pdf
English 82.3 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 361 bytes
2025-07-25 18:37
Delisting Announcement
Result of Tender Offer - Replacement
English 23.9 KB
2025-07-25 18:30
Declaration of Voting Results & Voting Rights Announcements
Correction: Result of Tender Offer, Total Voting Rights and Directors' Interest…
English 77.2 KB
2025-07-25 18:30
M&A Activity
Correction: Result of Tender Offer, Total Voting Rights and Directors' Interests
English 1.1 KB
2025-07-25 08:00
Share Issue/Capital Change
Result of Tender Offer, Total Voting Rights and Directors' Interests - Attachm…
English 68.6 KB
2025-07-25 08:00
Declaration of Voting Results & Voting Rights Announcements
Result of Tender Offer, Total Voting Rights and Directors' Interests
English 842 bytes

Automate Your Workflow. Get a real-time feed of all Benchmark Holdings Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Benchmark Holdings Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Benchmark Holdings Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Edesa Biotech, Inc. Logo
Develops treatments for inflammatory and immune diseases like Acute Respiratory Distress Syndrome.
United States of America
EDSA
Edgewise Therapeutics, Inc. Logo
Developing novel therapeutics for rare and serious muscle disorders.
United States of America
EWTX
Editas Medicine, Inc. Logo
Developing CRISPR-based genomic medicines to treat serious and rare genetic diseases.
United States of America
EDIT
Eevia Health Plc Logo
Manufactures validated polyphenol extracts from Arctic plants for the supplement & food industries.
Finland
EEVIA
Egetis Therapeutics Logo
Develops and commercializes drugs for serious rare diseases with unmet medical needs.
Sweden
EGTX
EIKEN CHEMICAL CO.,LTD. Logo
Manufacturer of clinical diagnostics, specializing in FIT systems for cancer and microbiological tests.
Japan
4549
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan
4523
Elanco Animal Health Inc Logo
Develops medicines, vaccines, and services to treat and prevent disease in pets and farm animals.
United States of America
ELAN
Eledon Pharmaceuticals, Inc. Logo
Develops immunomodulatory therapies to prevent organ rejection in transplant patients.
United States of America
ELDN
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC

Talk to a Data Expert

Have a question? We'll get back to you promptly.